Bortezomib Is a Successful Therapeutic Agent for Refractory Autoimmune Cytopenias in Children: A Single Center Experience  by Khandelwal, Pooja et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183S174254
Bortezomib Is a Successful Therapeutic Agent for
Refractory Autoimmune Cytopenias in Children: A Single
Center Experience
Pooja Khandelwal 1, Stella M. Davies 1, Rebecca A. Marsh 1,
Kasiani C. Myers 1, Javier El-Bietar 1, Sharat Chandra 1,
Parinda A. Mehta 1, Sonata Jodele 1, Ashish Kumar 1,
Jack Bleesing 1, Michael Jordan 1, Michael Grimley 2,
Ervin Steve Woodle 3, Rita Alloway 4, Alexandra Filipovich 1.
1 Bone Marrow Transplantation and Immune Deﬁciency,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
2 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
3Division of Surgery, University of Cincinnati, Cincinnati, OH;
4 University of Cincinnati, Cincinnati, OH
Refractory autoimmune cytopenias are a signiﬁcant com-
plication of allogeneic stem cell transplantation. Autor-
eactive plasma cells are hypothesized to be responsible for
persistent cytopenias. Bortezomib, a proteasome inhibitor,
has been used successfully to treat antibody mediated
rejection of renal allografts in adults. Seven patients, median
age 9 years (range 1.25- 25 years) received bortezomib at a
median of 85 days (range 14-178 days) from laboratory
conﬁrmation of autoimmune cytopenia(s) (Table 1). All
patients failed at least 2 standard treatments, including
rituximab (n¼4), IVIG (n¼7), corticosteroids (n¼7) and
plasmapheresis (n¼5). Six patients received a single dose of
rituximab at 375 mg/m2 on the ﬁrst day of therapy due to
presence of B cells. Four doses of bortezomib were admin-
istered (1.3 mg/m2) 72 hours apart, either subcutaneously
(n¼1) or intravenously (n¼6), and plasmapheresis was
performed in all patients 2 hours prior to drug adminis-
tration .Six patients (85%) responded with normalization of
cytopenia(s), at a median time of 11.5 days (range 3-20
days) for autoimmune neutropenia, and 27 days (rangeTable 1
Patient characteristics and type of autoimmune cytopenia.
Age
(years)
Pre/Post transplant
(Day of onset
after BMT)
Underlying
Diagnosis
Type of autoimmune
cytopenia
9 Post ( 143 days) Combined Immune
Deﬁciency ( CID)
Neutropenia
1.25 Post( 233 days) SCID Hemolytic anemia
17.6 Post (140 days) Relapsed AML Thrombocytopenia
Neutropenia
10 Post (156 days) SCID Thrombocytopenia
Neutropenia
1.25 Pre Evan’s syndrome Hemolytic anemia
Thrombocytopenia
25 Pre CID Thrombocytopenia
2.25 Pre Unspeciﬁed
Immune deﬁciency
Thrombocytopenia
Table 1
Control 0.001 mg/ml
Viability Apoptosis Death Viability
NGP 91.5% 7% 1.5 % 72%
IMR-5 63% 15% 22% 63%
SK-N-SH 71% 13% 13% 29%
SK-N-DOX 92% 3% 5% 31%
Patient A 40% 28% 16% 35%
Patient B 57% 14% 30% 29%13-133 days) for autoimmune thrombocytopenia. Two pa-
tients with autoimmune hemolytic anemia had a normal
reticulocyte count by 13 days and normal haptoglobin by an
average of 25 days from ﬁrst dose of bortezomib. While the
DAT continued to be positive, they remained transfusion
independent. Reoccurrence of cytopenia(s) occurred in 2
patients at an average of 53.5 days after achieving resolu-
tion. Adverse effects of bortezomib include cellulitis at the
subcutaneous injection site (n¼1), febrile neutropenia
(n¼1), Clostridium difﬁcle colitis (n¼1), transient thrombo-
cytopenia (n¼2) and pneumatosis intestinalis (n¼2). One
patient had asymptomatic BK viremia and 1 had a Klebsiella
bacteremia, both successfully treated. Two patients died at
173 and 347 days from ﬁrst dose of bortezomib, due to
encephalopathy leading to cardiorespiratory failure and
idiopathic pulmonary syndrome leading to respiratory fail-
ure respectively. Bortezomib is an effective therapeutic
agent for refractory autoimmune cytopenias. Further trials
are needed to evaluate efﬁcacy.255
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Bu is an alkylating agent for conditioning regimens in
transplantation. The purpose of this study was to evaluate
apoptosis and cell death in- vitro in four NB cell lines (NGP,
IMR-5, SK-N-SH and SKN-DOX) and two primary tumors
cell lines (Patient A and B) treated with Bu. Cells were
exposed in-vitro to Bu with various concentrations (0.001,
0.005, 0.01, 0.05, and 0.1 mg/ml). Cell viability was
assessed using trypan blue, apoptosis and cell death by
ﬂow cytometry via Annexin V and Propidium Iodide.
Samples were assessed at 6, 24, 48, and 72 hours. Un-
treated samples served as control. All experimentations
were in triplicate and mean values were used. Table 1
illustrates the median percent at 24 hours for the com-
parison of the lowest (0.001 mg/ml) to highest (0.1 mg/ml)
Bu dosage. Cell lines with a high percentage (> 50%) in
combination of apoptosis and cell death regardless of Bu
concentrations were considered sensitive (SK-N_SH, SK-N-
DOX, Patients A and B) while those with decreased per-
centage (<20%) of both were considered resistant (NGP,
IMR-5) to Bu. This methodology can be used to assess
prospective patients with NB and to determine if Bu should
be included in their conditioning regimens for autologous
hematopoietic stem cell transplants.0.1 mg/ml
Apoptosis Death Viability Apoptosis Death
25% 3% 80% 15% 5%
12% 21% 56% 21% 23%
33% 38% 20% 27% 56%
16% 41% 28% 17% 57%
42% 23% 42% 42% 24%
26% 41% 21% 22% 57%
